Roche Holding AG - Receives Ce Mark for Ventana Folr1 (Folr1-2.1) Rxdx Assay as First Ihc-Based Companion Diagnostic to Identify Ovarian Cancer Patients Eligible for Elahere
羅氏(adr) - 獲得Ventana Folr1 (Folr1-2.1) Rxdx Assay的Ce標誌，成爲首個基於IHC的伴隨診斷，用於識別適合接受Elahere的卵巢癌患者
